Low glycemic diet test for diabetes and body changes in CF
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This trial studies whether a low glycemic load (a specific way of choosing carbohydrates) improves blood sugar control and body composition in adults with cystic fibrosis–related diabetes. It may help reduce blood sugar problems and support healthier weight and body measurements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have cystic fibrosis confirmed by genetic testing
- You have pancreatic insufficiency and take pancreatic enzyme pills
- You meet the trial’s diabetes criteria (high blood sugar on a test, high A1c, or you use insulin)
- Your lung function is not severely reduced (FEV1 must be 50% predicted or higher)
- Your BMI is at least 18 (not underweight)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether changing eating habits—especially added sugar intake—affects health in adults with cystic fibrosis. It may help by testing a diet approach aimed at better outcomes related to metabolism and overall health.
This study looks at how the body handles sugar in people with cystic fibrosis related diabetes. Researchers want to learn more about glucose metabolism to improve care for people with CFRD.
This study tests how the body’s “incretin” hormones affect insulin (sugar control) in adults with cystic fibrosis and certain blood sugar patterns. It may help explain what drives diabetes risk in cystic fibrosis and how the body responds to these hormone signals.
This study tests if a continuous glucose monitor (CGM) along with a standard glucose drink test can better detect diabetes in people with cystic fibrosis. It is for adults who do not yet have diabetes and are generally healthy.
This study uses a continuous glucose monitor (CGM), a small sensor worn on the skin, to track blood sugar levels in people with cystic fibrosis (CF) who do not have diabetes or have prediabetes. The goal is to find patterns that might predict who will develop diabetes, so it can be caught earlier.
This Phase 2 trial tests a weekly GLP-1 medicine (dulaglutide) to improve blood sugar control in adults with cystic fibrosis (CF) who have trouble managing glucose. It may help people with CF-related prediabetes or diabetes by improving how their body handles sugar.
Hear when a new Cystic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.